H Borghaei Selected Research

Neoplasms (Cancer)

11/2023	Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.
1/2023	Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.
1/2016	Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma.
11/2014	A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

H Borghaei Research Topics

Disease

4	Neoplasms (Cancer) 11/2023 - 11/2014
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2023 - 01/2023
3	Disease Progression 10/2023 - 11/2014
1	Hepatocellular Carcinoma (Hepatoma) 01/2016

Drug/Important Bio-Agent (IBA)

3	NivolumabIBA 11/2023 - 01/2023
2	B7-H1 AntigenIBA 11/2023 - 01/2023
2	IpilimumabIBA 11/2023 - 01/2023
2	Monoclonal AntibodiesIBA 01/2016 - 11/2014
1	Aluminum Oxide (Sapphire)IBA 10/2023
1	cyclopropapyrroloindoleIBA 10/2023
1	sitravatinibIBA 10/2023
1	Docetaxel (Taxotere)FDA Link 10/2023
1	PlatinumIBA 10/2023
1	ascrinvacumabIBA 01/2016
1	Biomarkers (Surrogate Marker)IBA 01/2016
1	Activin Receptors (Activin Receptor)IBA 01/2016
1	CytokinesIBA 11/2014
1	Immunoglobulin G (IgG)IBA 11/2014
1	PF-04605412IBA 11/2014
1	IntegrinsIBA 11/2014

Therapy/Procedure

3	Drug Therapy (Chemotherapy) 11/2023 - 01/2023
2	Therapeutics 10/2023 - 01/2016